ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМП10.25789/YMJ.2023.83.15ymj-209Research ArticleАКТУАЛЬНАЯ ТЕМАACTUAL TOPICФакторы риска развития пневмонии у больных иммуновоспалительными ревматическими заболеваниями, получающих ГИБП в условиях COVID-19Risk factors for the development of pneumonia in patients with immuno-inflammatory rheumatic diseases receiving GIBP in conditions of COVID-19https://orcid.org/0000-0002-7080-777XКурочкинаЮ. Д.KurochkinaY. D.

КУРОЧКИНА Юлия Дмитриевна – к.м.н., н.с., врач-ревматолог

KUROCHKINA Yuliya Dmitrievna – PhD, rheumatology department, research scientist of the laboratory of connective tissue pathology of RICEL

juli_k@bk.ruhttps://orcid.org/0000-0002-4890-0847КоролевМ. А.KorolevM. A.

КОРОЛЕВ Максим Александрович – к.м.н., зам. руковод. НИИКЭЛ, зав. лаб., гл. внештат. ревматолог МЗ НСО

KOROLEV Maxim Aleksandrovich – MD, deputy director of RICEL, the leading rheumatologist of Novosibirsk region, head of the laboratory of connective tissue pathology of RICEL

https://orcid.org/0000-0002-6275-2924ЛетягинаЕ. А.LetyaginaE. A.

ЛЕТЯГИНА Елена Алексеевна – к.м.н., с.н.с., зав. отд.

LETYAGINA Elena Alekseevna - PhD, head of rheumatology department of RICEL, senior researcher at laboratory of connective tissue pathology of RICEL

https://orcid.org/0000-0003-0900-1600БанщиковаН. Е.BanshchikovaN. E.

БАНЩИКОВА Надежда Евгеньевна – м.н.с., врач-ревматолог

BANSHCHIKOVA Nadezhda Evgenievna – rheumatologist, junior researcher of the laboratory of connective tissue pathology of RICEL

https://orcid.org/0000-0002-7213-7482СизиковА. Э.SizikovA. E.

СИЗИКОВ Алексей Эдуардович – к.м.н., зав. отд.

SIZIKOV Alexey Eduardovich – PhD, head of rheumatology department of RIFCI

https://orcid.org/0000-0002-2570-8035БогодероваЛ. А.BogoderovaL. A.

БОГОДЕРОВА Лариса Александровна –зав. отд.

BOGODEROVA Larisa Aleksandrovna – PhD, head of rheumatology department

https://orcid.org/0000-0001-6330-1044УбшаеваЮ. Б.UbshaevaY. B.

УБШАЕВА Юлия Борисовна – к.м.н., н.с., врач-ревматолог

UBSHAEVA Yuliya Borisovna – PhD, rheumatology, research scientist at laboratory of connective tissue pathology of RICEL

https://orcid.org/0000-0001-6606-7185ОмельченкоВ. О.OmelchenkoV. O.

ОМЕЛЬЧЕНКО Виталий Олегович – к.м.н., н.с., врач-ревматолог

OMELCHENKO Vitaliy Olegovich – PhD, rheumatologist, research scientist at laboratory of connective tissue pathology of RICEL

https://orcid.org/0000-0003-1099-3256АкимоваА. А.AkimovaA. A.

АКИМОВА Анна Александровна – м.н.с., врач-ревматолог

AKIMOVA Anna Aleksandrovna – rheumatologist, junior researcher at laboratory of connective tissue pathology of RICEL

https://orcid.org/0000-0002-5213-5658МуллагалиевА. А.MullagalievA. A.

МУЛЛАГАЛИЕВ Арсен Арсенович – м.н.с.

MULLAGALIEV Arsen Arsenovich – junior researcher of the laboratory at pharmacological modeling and screening of bioactive molecules of RICEL

https://orcid.org/0000-0003-3797-6392ЧумасоваО. А.ChumasovaO. A.

ЧУМАСОВА Оксана Александровна – к.м.н., врач-ревматолог

CHUMASOVA Oxana Aleksandrovna – PhD, rheumatologist department of RIFCI

https://orcid.org/0000-0002-8633-0662ИльинаН. А.IlyinaN. A.

ИЛЬИНА Надежда Александровна – врач-ревматолог

LYINA Nadezda Aleksandrovna – rheumatologist department of RIFCI

НИИ клинической и экспериментальной лимфологии – филиал ФИЦ Институт цитологии и генетики СО РАНРоссияResearch Institute of Clinical and Experimental Lymрhology – Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of SciencesRussian FederationНИИ фундаментальной и клинической иммунологииРоссияFederal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical ImmunologyRussian FederationГос. Новосибирская обл. клинич. б-цаРоссияState Novosibirsk Regional Clinical HospitalRussian Federation202305022025036164Copyright © Курочкина Ю.Д., Королев М.А., Летягина Е.А., Банщикова Н.Е., Сизиков А.Э., Богодерова Л.А., Убшаева Ю.Б., Омельченко В.О., Акимова А.А., Муллагалиев А.А., Чумасова О.А., Ильина Н.А., 20252025Курочкина Ю.Д., Королев М.А., Летягина Е.А., Банщикова Н.Е., Сизиков А.Э., Богодерова Л.А., Убшаева Ю.Б., Омельченко В.О., Акимова А.А., Муллагалиев А.А., Чумасова О.А., Ильина Н.А.Kurochkina Y.D., Korolev M.A., Letyagina E.A., Banshchikova N.E., Sizikov A.E., Bogoderova L.A., Ubshaeva Y.B., Omelchenko V.O., Akimova A.A., Mullagaliev A.A., Chumasova O.A., Ilyina N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/209

Выполнен ретроспективный анализ базы данных регистра пациентов с иммуновоспалительными ревматическими заболеваниями, получающих терапию генно-инженерными биологическими препаратами на территории Новосибирской области, многие из которых имели указания о перенесенной пневмонии за период с 01.04.2020 по 31.12.2020 г.

Показано статистически значимое увеличение риска развития пневмонии у пациентов в возрасте старше 60 лет и у получавших ритуксимаб, в то время как терапия ингибиторами ФНО-α значимо снижала риск развития пневмонии.

A retrospective analysis of the database of the register of patients with immuno-inflammatory rheumatic diseases receiving treatment with biologic disease-modifying anti-rheumatic drugs in the Novosibirsk region was carried out, which included 318 patients, 94 of whom had indications of pneumonia during the period from 01.04.2020 to 31.12.2020.

There was a statistically significant increase in the risk of developing pneumonia over the age of 60 years and in patients receiving rituximab, while the therapy with TNF-α inhibitors significantly reduced the risk of developing pneumonia.

COVID-19пневмонияиммуновоспалительные ревматические заболеваниягенно-инженерные биологические препаратыCOVID-19pneumoniaimmune-inflammatory rheumatic diseasesbiologic disease-modifying anti-rheumatic drugsРабота выполнена в рамках Государственного задания НИИКЭЛ-филиал ИЦиГ СО РАН. Тема № FWNR-2023-0009.ReferencesИммуновоспалительные ревматические заболевания и COVID-19: анализ клинических исходов по данным регистра пациентов Новосибирской области, получающих терапию генно-инженерными биологическими препаратами/Королев М.А.[и др]. // Терапевтич. архив. 2022. Т. 94. №5. C. 636-641. doi: 10.26442/00403660.2022.05.201502doi: 10.26442/00403660.2022.05.201502 Immune-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs /Korolev M.A. [et al] // Ter. Arkh. 2022. Vol. 94. No. 5. P. 636–641.Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России»// Насонов Е.Л. [и др.]//Науч.-практич. ревматология. 2021. Т 59. No3. С 239-254. https://doi.org/10.47360/1995-4484-2021-239-254https://doi.org/10.47360/1995-4484-2021-239-254 Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia / Nasonov E.L [et al.]// Rheumatol. Sci. Pract. 2021. Vol. 59. No 3. P. 239–254.Насонов ЕЛ, Ананьева ЛП, Авдеев СН. Интерстициальные заболевания легких при ревматоидном артрите: мультидисциплинарная проблема ревматологии и пульмонологии.//Там же. 2022. Т 60. No 6. С. 517–534: doi: 10.47360/1995-4484-2022-1doi: 10.47360/1995-4484-2022-1 Nasonov E.L., Ananyeva L.P., Avdeev S.N. Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology // Ibid. 2022. Vol. 60. No. 6. P. 517– 534.Насонов Е.Л., Авдеева А.С. Деплеция В-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (COVID-19)// Там же. 2021. Т 59. No 4. C 384–393. https://doi.org/10.47360/1995-4484-2021-384-393https://doi.org/10.47360/1995-4484-2021-384-393 Nasonov E.L., Avdeeva A.S. B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19) // Ibid. 2021. Vol. 59. Vol. 4. P. 384–393.Течение и исходы COVID-19 у пациентов с иммуновоспалительными ревматическими заболеваниями: предварительные данные регистра НИИР/АРР-COVID-19 и обзор литературы/ Насонов Е.Л [и др.]//Там же. 2021 Т.59 No 6. С. 666-675. https://doi.org/10.47360/1995-4484-2021-666-675https://doi.org/10.47360/1995-4484-2021-666-675 Nasonov E.L. et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review // Ibid. 2021b. Vol. 59. Vol. 6. P. 666–675.Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases / Boyarsky B.J. [et al.] //Ann. Rheum. Dis. 2021. Vol. 80. No. 8. P. 1098–1099. https://doi.org/10.1136/annrheumdis-2021-220289Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases / Boyarsky B.J. [et al.] //Ann. Rheum. Dis. 2021. Vol. 80. No. 8. P. 1098–1099. https://doi.org/10.1136/annrheumdis-2021-220289Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy / Galarza-Delgado D.Á [et al.] // Clin. Rheumatol. 2021. Vol. 40. № 3. P. 1197–1199. Available from: http://link.springer.com/10.1007/s10067-020-05510-9Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy / Galarza-Delgado D.Á [et al.] // Clin. Rheumatol. 2021. Vol. 40. № 3. P. 1197–1199. Available from: http://link.springer.com/10.1007/s10067-020-05510-9Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry/ Gianfrancesco M [et al.]// Ann. Rheum. Dis. 2020. Vol. 79. No. 7. P. 859–866. https://doi.org/10.1136/annrheumdis-2020-217871Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry/ Gianfrancesco M [et al.]// Ann. Rheum. Dis. 2020. Vol. 79. No. 7. P. 859–866. https://doi.org/10.1136/annrheumdis-2020-217871Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study/ Zhou F. [et al.] // Lancet. 2020. Vol. 395. No. 10229. P. 1054–1062. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study/ Zhou F. [et al.] // Lancet. 2020. Vol. 395. No. 10229. P. 1054–1062. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies / Monti S [et al.]// Ann. Rheum. Dis. 2020. Vol. 79. No. 5. P. 667– 668. https://doi.org/10.1136/annrheumdis-2020-217424Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies / Monti S [et al.]// Ann. Rheum. Dis. 2020. Vol. 79. No. 5. P. 667– 668. https://doi.org/10.1136/annrheumdis-2020-217424Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation / Eslambolchi A [et al.] // J. Thromb. Thrombolysis. 2021. Vol. 51. No. 2. P. 339–348. Available from: https://link.springer.com/10.1007/s11239-020-02289-zCoronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation / Eslambolchi A [et al.] // J. Thromb. Thrombolysis. 2021. Vol. 51. No. 2. P. 339–348. Available from: https://link.springer.com/10.1007/s11239-020-02289-zCOVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes / Haberman R.H. [et al.] // Arthritis Rheumatol. 2020. Vol. 72. No. 12. P. 1981–1989. https://doi.org/10.1002/art.41456COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes / Haberman R.H. [et al.] // Arthritis Rheumatol. 2020. Vol. 72. No. 12. P. 1981–1989. https://doi.org/10.1002/art.41456EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update / Landewé R.B.M [et al.] // Ann. Rheum. Dis. 2022. С. annrheumdis-2021-222006. https://doi.org/10.1136/annrheumdis-2021-222006EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update / Landewé R.B.M [et al.] // Ann. Rheum. Dis. 2022. С. annrheumdis-2021-222006. https://doi.org/10.1136/annrheumdis-2021-222006High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study/ Loarce-Martos J [et al.]// Rheumatol. Int. 2020. Vol. 40. No. 12. P. 2015–2021. Available from: http://link.springer.com/10.1007/s00296-020-04699-xHigh rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study/ Loarce-Martos J [et al.]// Rheumatol. Int. 2020. Vol. 40. No. 12. P. 2015–2021. Available from: http://link.springer.com/10.1007/s00296-020-04699-xLongterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials / VOLLENHOVEN R.F. van [et al.]// J. Rheumatol. 2010. Vol. 37. No. 3. P. 558–567. https://doi.org/10.3899/jrheum.090856Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials / VOLLENHOVEN R.F. van [et al.]// J. Rheumatol. 2010. Vol. 37. No. 3. P. 558–567. https://doi.org/10.3899/jrheum.090856Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19 // Science (80-). 2020. Vol. 368. No. 6490. P. 473–474. https://doi.org/10.1126/science.abb8925Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19 // Science (80-). 2020. Vol. 368. No. 6490. P. 473–474. https://doi.org/10.1126/science.abb8925Murakami M., Kamimura D., Hirano T. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines // Immunity. 2019. Vol. 50. No. 4. P. 812–831. Available from: https://linkinghub.elsevier.com/retrieve/pii/S107476131930144XMurakami M., Kamimura D., Hirano T. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines // Immunity. 2019. Vol. 50. No. 4. P. 812–831. Available from: https://linkinghub.elsevier.com/retrieve/pii/S107476131930144XPathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients /Zhou Y. [et al.] // Natl. Sci. Rev. 2020b. Vol. 7. No. 6. P. 998–1002. doi: 10.1093/nsr/nwaa041Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients /Zhou Y. [et al.] // Natl. Sci. Rev. 2020b. Vol. 7. No. 6. P. 998–1002. doi: 10.1093/nsr/nwaa041Pathological evidence for residual SARSCoV-2 in pulmonary tissues of a ready-for-discharge patient /Yao X.-H. [et al.] // Cell Res. 2020. Vol. 30. No. 6. P. 541–543. DOI: 10.1038/s41422-020-0318-5Pathological evidence for residual SARSCoV-2 in pulmonary tissues of a ready-for-discharge patient /Yao X.-H. [et al.] // Cell Res. 2020. Vol. 30. No. 6. P. 541–543. DOI: 10.1038/s41422-020-0318-5Pathological findings of COVID-19 associated with acute respiratory distress syndrome/ Xu Z. [et al.] // Lancet Respir. Med. 2020. Vol. 8. No. 4. P. 420–422. DOI: 10.1016/S2213-2600(20)30076-XPathological findings of COVID-19 associated with acute respiratory distress syndrome/ Xu Z. [et al.] // Lancet Respir. Med. 2020. Vol. 8. No. 4. P. 420–422. DOI: 10.1016/S2213-2600(20)30076-XPre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients/ Y. Nguyen [et al.] // Clinical Microbiology and Infection.2022. Vol. 28. P. 1654.e1e1654.e4. https://doi.org/10.1016/j.cmi.2022.07.015Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients/ Y. Nguyen [et al.] // Clinical Microbiology and Infection.2022. Vol. 28. P. 1654.e1e1654.e4. https://doi.org/10.1016/j.cmi.2022.07.015SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response/ Bonelli M.M [et al.] // Ann. Rheum. Dis. 2021. Vol. 80. No. 10. P. 1355–1356. https://doi.org/10.1136/annrheumdis-2021-220408SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response/ Bonelli M.M [et al.] // Ann. Rheum. Dis. 2021. Vol. 80. No. 10. P. 1355–1356. https://doi.org/10.1136/annrheumdis-2021-220408

The authors declare that there are no conflicts of interest present.